Predictive factors of cytotoxic damage in radioactive iodine treatment of differentiated thyroid cancer patients

Monzen,Satoru; Mariya,Yasushi; Wojcik,Andrzej; Kawamura,Chika; Nakamura,Ayumi; Chiba,Mitsuru; Hosoda,Masahiro; Takai,Yoshihiro

doi:10.3892/mco.2015.499

Predictive factors of cytotoxic damage in radioactive iodine treatment of differentiated thyroid cancer patients

Authors:
- Satoru Monzen
- Yasushi Mariya
- Andrzej Wojcik
- Chika Kawamura
- Ayumi Nakamura
- Mitsuru Chiba
- Masahiro Hosoda
- Yoshihiro Takai
View Affiliations

Affiliations: Department of Radiological Life Sciences, Division of Medical Life Sciences, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan, Centre for Radiation Protection Research, MBW Department, Stockholm University, SE‑106 91 Stockholm, Sweden, Department of Biomedical Sciences, Division of Medical Life Sciences, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan, Department of Radiology and Radiation Oncology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036‑8562, Japan
Published online on: January 27, 2015 https://doi.org/10.3892/mco.2015.499
Pages: 692-698

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Radioactive iodine (131I) therapy in patients suffering from differentiated thyroid cancer (DTC) is a targeted treatment commonly used for thyroid ablation and locoregional and distant metastatic spread management. Despite a significant proportion of the 131I dose entering the circulation, there is currently no detailed information regarding its effect on the blood cell system. In order to assess the cytotoxic effects of 131I therapy on the circulatory system, blood cell levels, thyroid‑related hormones and CD45+ cell cytotoxicity were estimated in blood collected from patients with DTC. The micronuclei (MN) frequency of the peripheral blood CD45+ cell fraction was significantly increased after 30 days of 131I therapy compared to that prior to treatment, although a strong individual variation was observed. A significantly negative correlation between MN frequency and the level of platelets and plateletcrit was observed; however, there was no such correlation with thyroid‑related hormones. These results suggest that the correlation between MN frequency and the platelet system may serve as a biomarker of exposure and, possibly, of sensitivity in DTC patients undergoing 131I therapy following thyroid and lymph node surgery.

View Figures

View References

1	Sabra MM, Grewal RK, Ghossein RA and Tuttle RM: Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases. Thyroid. 24:1088–1095. 2014. View Article : Google Scholar : PubMed/NCBI
2	Prpic M, Dabelic N, Stanicic J, Jukic T, Milosevic M, et al: Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid: a comparison of ablation success with different activities of radioiodine (I-131). Ann Nucl Med. 26:744–751. 2012. View Article : Google Scholar : PubMed/NCBI
3	Lee SM, Lee JW, Kim SY, Han SW and Bae WK: Prediction of risk for symptomatic sialadenitis by post-therapeutic dual (131)I scintigraphy in patients with differentiated thyroid cancer. Ann Nucl Med. 27:700–709. 2013. View Article : Google Scholar : PubMed/NCBI
4	Bonnema SJ and Hegedus L: Radioiodine therapy in benign thyroid diseases: effects, side effects and factors affecting therapeutic outcome. Endocr Rev. 33:920–980. 2012. View Article : Google Scholar : PubMed/NCBI
5	Nagayama H, Ooi J, Tomonari A, et al: Severe immune dysfunction after lethal neutron irradiation in a JCO nuclear facility accident victim. Int J Hematol. 76:157–164. 2002. View Article : Google Scholar : PubMed/NCBI
6	Zarybnicka L, Sinkorova Z, Sinkora J, et al: Sensitivity of porcine peripheral blood leukocytes to gamma irradiation in vivo, in vitro and ex vivo. Int J Radiat Biol. 87:491–498. 2011. View Article : Google Scholar : PubMed/NCBI
7	Watanabe N, Kanegane H, Kinuya S, et al: The radiotoxicity of ¹³¹I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes. J Nucl Med. 45:608–611. 2004.PubMed/NCBI
8	Erselcan T, Sungu S, Ozdemir S, Turgut B, Dogan D and Ozdemir O: Iodine-131 treatment and chromosomal damage: in vivo dose-effect relationship. Eur J Nucl Med Mol Imaging. 31:676–684. 2004. View Article : Google Scholar : PubMed/NCBI
9	Ballardin M, Gemignani F, Bodei L, et al: Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131. Mutat Res. 514:77–85. 2002. View Article : Google Scholar : PubMed/NCBI
10	Gutierrez S, Carbonell E, Galofre P, Creus A and Marcos R: Cytogenetic damage after 131-iodine treatment for hyperthyroidism and thyroid cancer. A study using the micronucleus test. Eur J Nucl Med. 26:1589–1596. 1999. View Article : Google Scholar : PubMed/NCBI
11	M'Kacher R, Schlumberger M, Legal JD, Violot D, Beron-Gaillard N, et al: Biologic dosimetry in thyroid cancer patients after repeated treatments with iodine-131. J Nucl Med. 39:825–829. 1998.PubMed/NCBI
12	Vrndić OB, Milošević-Djordjević OM, Mijatović Teodorović LC, et al: Correlation between micronuclei frequency in peripheral blood lymphocytes and retention of 131-I in thyroid cancer patients. Tohoku J Exp Med. 229:115–124. 2013. View Article : Google Scholar : PubMed/NCBI
13	Takahashi K, Monzen S, Eguchi-Kasai K, Abe Y and Kashiwakura I: Severe damage of human megakaryocytopoiesis and thrombopoiesis by heavy-ion beam radiation. Radiat Res. 168:545–551. 2007. View Article : Google Scholar : PubMed/NCBI
14	Monzen S, Yoshino H, Kasai-Eguchi K and Kashiwakura I: Characteristics of myeloid differentiation and maturation pathway derived from human hematopoietic stem cells exposed to different linear energy transfer radiation types. PLoS One. 8:e593852013. View Article : Google Scholar : PubMed/NCBI
15	EPR-BIODOSIMETRY 2011, . Cytogenetic Dosimetry: Applications in Preparedness for and Response to Radiation Emergencies. IAEA; Vienna: 2011
16	Fonseca TL, Correa-Medina M, Campos MP, et al: Coordination of hypothalamic and pituitary T3 production regulates TSH expression. J Clin Invest. 123:1492–1500. 2013. View Article : Google Scholar : PubMed/NCBI
17	Monzen S and Kashiwakura I: Radioprotective effects of (-)-epigallocatechin-3-gallate on human erythrocyte/granulocyte lineages. Radiat Prot Dosimetry. 152:224–228. 2012. View Article : Google Scholar : PubMed/NCBI
18	Takahashi K, Monzen S, Hayashi N and Kashiwakura I: Correlations of cell surface antigens with individual differences in radiosensitivity in human hematopoietic stem/progenitor cells. Radiat Res. 173:184–190. 2010. View Article : Google Scholar : PubMed/NCBI
19	Vrndić O, Milošević-Djordjević O, Djurdjević P, et al: Radioiodine therapy accelerates apoptosis in peripheral blood lymphocytes of patients with differentiated thyroid cancer. Neoplasma. 60:568–575. 2013. View Article : Google Scholar : PubMed/NCBI
20	Hazawa M, Hosokawa Y, Monzen S, Yoshino H and Kashiwakura I: Regulation of DNA damage response and cell cycle in radiation-resistant HL60 myeloid leukemia cells. Oncol Rep. 28:55–61. 2012.PubMed/NCBI
21	Stiff T, Cerosaletti K, Concannon P, O'Driscoll M and Jeggo PA: Replication independent ATR signaling leads to G2/M arrest requiring Nbs1, 53BP1 and MDC1. Hum Mol Genet. 17:3247–3253. 2008. View Article : Google Scholar : PubMed/NCBI
22	Monzen S, Osuda K, Miyazaki Y, et al: Radiation sensitivities in the terminal stages of megakaryocytic maturation and platelet production. Radiat Res. 172:314–320. 2009. View Article : Google Scholar : PubMed/NCBI
23	Maia GA, Renó Cde O, Medina JM, et al: The effect of gamma radiation on the lipid profile of irradiated red blood cells. Ann Hematol. 93:753–760. 2014. View Article : Google Scholar : PubMed/NCBI
24	Dorgalaleh A, Mahmoodi M, Varmaghani B, et al: Effect of thyroid dysfunctions on blood cell count and red blood cell indices. Iran J Ped Hematol Oncol. 3:73–77. 2013.PubMed/NCBI
25	Schindhelm RK, ten Boekel E, Heima NE, van Schoor NM and Simsek S: Thyroid hormones and erythrocyte indices in a cohort of euthyroid older subjects. Eur J Intern Med. 24:241–244. 2013. View Article : Google Scholar : PubMed/NCBI
26	Alcelik A, Aktas G, Eroglu M, et al: Platelet function in euthyroid patients undergoing thyroidectomy in women. Eur Rev Med Pharmacol Sci. 17:2350–2353. 2013.PubMed/NCBI
27	Pilli T, Brianzoni E, Capoccetti F, et al: A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab. 92:3542–3546. 2007. View Article : Google Scholar : PubMed/NCBI